Trial results for ubrogepant (Ubrelvy) in the acute treatment of migraine were published on 2019-01-01 in the New England Journal of Medicine. This publication detailed findings from the ACHIEVE I study, which specifically evaluated the efficacy, safety, and tolerability of oral ubrogepant for this condition.
Background
Ubrogepant is an oral medication that has been investigated for the acute treatment of migraine. Migraine is a a neurological disorder characterized by recurrent moderate to severe headaches, often accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound. Effective acute treatments are crucial for patients to manage individual migraine attacks. The publication of the ACHIEVE I study results provides important data concerning ubrogepant's profile in managing these acute migraine attacks. The study's comprehensive focus on "Efficacy, Safety, and Tolerability" highlights the thorough assessment undertaken for ubrogepant as a potential therapeutic option.
Trial design
The published study, identified as ACHIEVE I, was described as an "Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine." This pivotal publication details the findings from a trial designed to assess the performance of ubrogepant in patients experiencing acute migraine. The study aimed to provide comprehensive data on how well ubrogepant works (efficacy), how safe it is, and how well patients tolerate the treatment when used for acute migraine attacks.
What this means
The publication of the ACHIEVE I study results in a prominent medical journal like the New England Journal of Medicine signifies a substantial contribution to the understanding of ubrogepant for the acute treatment of migraine. Clinicians and researchers now have access to detailed data on its efficacy, safety, and tolerability, which is crucial for evaluating its role as a therapeutic option for patients experiencing acute migraine attacks. This information supports informed decision-making regarding the use of ubrogepant and its potential benefits and risks in clinical practice. The availability of these comprehensive findings allows healthcare providers to better assess ubrogepant's place within the existing landscape of acute migraine treatments.
Source
The information for this article is derived from a publication in the New England Journal of Medicine, which was indexed on PubMed on 2019-01-01. The source document, titled "Ubrogepant for the Treatment of Migraine," is available through the PubMed database hosted at pubmed.ncbi.nlm.nih.gov.